First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Autor: Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Rodon JA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mott F; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fan Y; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Fan J; Clinical Department, TransThera Sciences (US), Inc., Gaithersburg, MA, USA., Peng P; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Wang H; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Ni S; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Sun C; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Qiang X; Biology Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Levin WJ; Clinical Department, CRC Oncology, San Diego, CA, USA., Ngo B; Clinical Department, CRC Oncology, San Diego, CA, USA., Ru QC; Clinical Department, CRC Oncology, San Diego, CA, USA., Wu F; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Javle MM; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e514-e525.

Exploring human plasma proteome strategies: high efficiency in-solution digestion protocol for multi-dimensional protein identification technology.

Autor: Ru QC; Windber Research Institute, PA 15963, USA. c.ru@wriwindber.org, Zhu LA, Katenhusen RA, Silberman J, Brzeski H, Liebman M, Shriver CD

Publikováno v: Journal of chromatography. A [J Chromatogr A] 2006 Apr 14; Vol. 1111 (2), pp. 175-91. Date of Electronic Publication: 2005 Jul 26.